|
Predictive evaluation of quantitative spatial profiling of the tumor microenvironment by multiplex immunofluorescence in recurrent glioblastoma treated with PD-1 inhibitors. |
|
|
No Relationships to Disclose |
|
|
Employment - Navigate BioPharma |
Stock and Other Ownership Interests - Novartis |
|
|
Employment - Navigate BioPharma |
Stock and Other Ownership Interests - Novartis |
|
|
Employment - Navigate BioPharma |
Stock and Other Ownership Interests - Novartis |
|
|
Employment - Navigate BioPharma |
|
|
Employment - Navigate BioPharma |
Stock and Other Ownership Interests - Novartis |
|
|
Employment - Navigate BioPharma |
Stock and Other Ownership Interests - Novartis |
|
|
Employment - Navigate BioPharma |
Stock and Other Ownership Interests - Biogen; Novartis |
Patents, Royalties, Other Intellectual Property - Novartis |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Alexion Pharmaceuticals; Guidepoint Global; Merck; Novocure; Regeneron; tocagen |
Speakers' Bureau - Prime Oncology |
Research Funding - Bristol-Myers Squibb; Celldex; FORMA Therapeutics; Merck; Northwest Biotherapeutics; tocagen |
Travel, Accommodations, Expenses - Oncoceutics |
(OPTIONAL) Uncompensated Relationships - Northwest Biotherapeutics |